Literature DB >> 11887986

Systemic treatment and new developments in advanced prostate cancer.

C N Sternberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11887986     DOI： 10.1016/s0959-8049(01)80016-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  2 in total

1.  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.

Authors:  Franklin M Chu; Joel Picus; Paula M Fracasso; Robert Dreicer; Zhihui Lang; Brenda Foster
Journal:  Invest New Drugs       Date:  2010-02-11       Impact factor: 3.850

2.  Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cells.

Authors:  J F Curtin; T G Cotter
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.